PRKCH

Across TCGA pan-cancer cohorts, PRKCH Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRKCH data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher PRKCH Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRKCH expression acts as an unfavorable survival marker.

DLBC, ESCA, and COAD are the cancer types where PRKCH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
ESCA	DFS	Median	All	0.075	0.533	<.001	12	view →
COAD	OS	Median	III,IV	0.221	0.782	.013	9	view →
SKCM	OS	Median	IV	0.415	0.861	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRKCH–DLBC (DFS)

Open the DLBC breakdown →